WASHINGTON D.C. – The Canadian pharmaceutical industry has been put on high alert following President Donald Trump's announcement of a potential 200% tariff on pharmaceutical imports. Although Canada may not be the primary target, there's growing concern that this measure could pose a severe threat to the Canadian pharmaceutical sector.

Jim Keon, President of the Canadian Generic Pharmaceutical Association, analyzed that this tariff threat stems from the U.S. effort to reduce its reliance on pharmaceutical imports from countries like China and India. However, he warned that Canada could inadvertently suffer damage in this process. Trump suggested the 200% tariff idea last Tuesday (July 8), stating that pharmaceutical companies would be given a grace period of up to 18 months before the tariffs are implemented.

According to Keon, Canadian pharmaceutical exports account for less than 5% of all generic drugs sold in the U.S. However, he explained that if access to the U.S. market is blocked, some Canadian pharmaceutical companies might find it difficult to continue producing specific generic drugs for their domestic market. This implies that beyond just a decrease in exports, it could disrupt Canada's own domestic drug supply chain.

Trump's 'America First' and the Pharmaceutical Industry 

This move by the Trump administration is an extension of its 'America First' policy. Efforts to encourage domestic production and reduce foreign dependence have intensified, especially since the pandemic highlighted the importance of supply chain stability. As pharmaceuticals are essential items directly linked to national security, the desire to strengthen domestic production capabilities is understandable.

However, such a high tariff of 200% effectively signals an intention to completely block imports, which could cause significant disruption to the global pharmaceutical supply chain. Critics argue that this would affect not only Canada but also all countries exporting pharmaceuticals to the U.S., and could ultimately lead to higher drug prices in the U.S. Given that the pharmaceutical industry requires high-level technology and massive investment, there are significant concerns about the side effects of short-term policy changes.

Characteristics of Canada's Pharmaceutical Industry and Response Strategy 

The Canadian pharmaceutical industry primarily excels in generic drug production, and the U.S. is one of the largest markets for Canadian pharmaceutical exports. If access to the U.S. market becomes difficult, Canadian pharmaceutical companies may have to reduce their production scale or even cease production of certain items. This, in turn, could narrow the range of available drugs in Canada and potentially lead to drug shortages.

Currently, ongoing economic and security agreements between Canada and the U.S. offer hope for resolving this crisis. Keon expressed hope that pharmaceuticals would be excluded from tariffs through these agreements. The Canadian government is expected to make every effort to protect its domestic pharmaceutical industry and maintain the stability of pharmaceutical trade between the two countries through close negotiations with the U.S. As seen in the renegotiation of the North American Free Trade Agreement (NAFTA), the establishment of exceptional provisions, considering the unique nature of the economic relationship between the two countries, will be crucial.

[Copyright (c) Global Economic Times. All Rights Reserved.]